HTFL logo

Heartflow, Inc. (HTFL)

$47.07

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on HTFL

Market cap

$4.14B

EPS

1.76

P/E ratio

--

Price to sales

20.39

Dividend yield

--

Beta

2.495107

Price on HTFL

Previous close

$46.86

Today's open

$46.39

Day's range

$45.80 - $48.05

52 week range

$20.13 - $60.66

Profile about HTFL

CEO

--

Employees

843

Headquarters

San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

87887561

Issue type

Common Stock

HTFL industries and sectors

Healthcare

Healthcare Providers & Services

News on HTFL

HeartFlow: A Post Q3 Assessment

HeartFlow, Inc. has rallied impressively since its August IPO, defying typical post-IPO trends, but had a big post-Q3 selloff on Friday. HTFL specializes in non-invasive coronary artery disease diagnostics, leveraging advanced AI-driven 3D heart modeling technology. The company is delivering 50% sales growth but still lacks profitability.  The stock enjoys strong analyst firm support.

news source

Seeking Alpha • Nov 17, 2026

news preview

HeartFlow: 3 Key Takeaways for Long-Term Investors

Full-year 2026 revenue guidance raised to $262 million to $264 million. Plaque Analysis reduced major cardiovascular events by 34% at one year.

news source

The Motley Fool • Nov 14, 2026

news preview

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow NASDAQ: HTFL raised its 2026 revenue forecast after reporting third-quarter sales growth of 57%, citing wider adoption of its Plaque Analysis product, durable demand for FFRct and growth in coronary CT angiography.

news source

MarketBeat • Nov 13, 2026

news preview

HeartFlow, Inc. (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 13, 2026

news preview

Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Highlights Total revenue of $72.9 million, a 57% increase year-over-year Gross margin of 83.6%, non-GAAP gross margin of 83.8% Net operating loss of $13.8 million; non-GAAP net operating loss of $5.0 million 2026 Annual Guidance Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year) Non-GAAP gross margin of approximately 82.5%, compared to previous guidance of approximately 82% “Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters,” said John Farquhar, President and CEO of Heartflow.

news source

GlobeNewsWire • Nov 12, 2026

news preview

HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates

HeartFlow (HTFL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.27 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Voya Small Cap Growth Strategy Q3 2026 Contributors And Detractors

For the quarter ended September 30, 2026, the Fund underperformed the Index on a NAV basis, due to stock selection. Negative stock selection in the industrials, financials, and materials sectors was the leading detractor from performance along with an overall negative allocation effect. Stock selection in the consumer staples and real estate sectors and holding cash were the largest contributors to performance.

news source

Seeking Alpha • Nov 12, 2026

news preview

AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry

First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs.

news source

GlobeNewsWire • Nov 2, 2026

news preview

TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions

news source

GlobeNewsWire • Nov 1, 2026

news preview

Boston Scientific announces results for third quarter 2026

MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and organic2 basis, all compared to the prior year period.

news source

PRNewsWire • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Heartflow, Inc.

Open an M1 investment account to buy and sell Heartflow, Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in HTFL on M1